2 year event-free survival was 926 % ( 95 % CI 896-957 ) for treatment including doxorubicin and 882 % ( 845-921 ) for treatment excluding doxorubicin , a difference of 44 % ( 95 % CI 04-93 ) that did not exceed the predefined 10 % margin .